Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Squamous Cell Cancer 1Head and Neck Neoplasms 1

Interventions

Radiotherapy 11Cisplatin 11Radiotherapy, Intensity-Modulated 6Radiation 5Fluorouracil 5Cetuximab 5pembrolizumab 4Carboplatin 3fludarabine phosphate 2fludarabine 2durvalumab 2aldesleukin 2Vorinostat 2Surveys and Questionnaires 2Restraint, Physical 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Paclitaxel 2Nivolumab 2Nicotine 2Immunohistochemistry 2Hydroxyurea 2Gene Expression Profiling 2Drug Therapy 2Docetaxel 2Cyclophosphamide 2Counseling 2Celecoxib 2Bupropion 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Oropharyngeal Neoplasms × MEDI0457 × Clear all
NCT03162224 2022-08-25

Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer

MedImmune LLC

Phase 1/2 Completed
35 enrolled 25 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Oropharyngeal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡